Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
75
datasets available to search
ShareScore release 0.9.0
Dataset results
75 results for “gallates”
Ir and NMR for article Synthesis and Biological Activity Evaluation of New Isatin-Gallate Hybrids as Antioxidant and Anticancer Agents (in vitro) and In-silico Study as Anticancer Agents and Coronavirus Inhibitors
<p>this is IR and NMR data for article titled <strong>Synthesis and Biological Activity Evaluation of New Isatin-Gallate Hybrids as Antioxidant and Anticancer Agents (<em>in vitro</em>) and In-silico Study as Anticancer Agents and Coronavirus Inhibitors </strong></p> <p> </p>
Effect of Epigallocatechin-Gallate on Inner Retinal Function in Ocular Hypertension and Early Glaucoma
ClinicalTrials.gov study NCT00476138. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Treatment of Epidermolysis Bullosa Dystrophica by Polyphenon E (Epigallocatechin 3 Gallate)
ClinicalTrials.gov study NCT00951964. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Effects of Vitamin D, Epigallocatechin Gallate, Vitamin B6, and D-Chiro-inositol Combination on Uterine Fibroids
ClinicalTrials.gov study NCT05409872. IPD Sharing: NO. Countries: 1. Publications: 4.
Sunphenon Epigallocatechin-gallate (EGCg) in Relapsing-remitting Multiple Sclerosis (SuniMS Study)
ClinicalTrials.gov study NCT00525668. IPD Sharing: Not stated. Countries: 1. Publications: 1.
FRIEND: Fibroids and Unexplained Infertility Treatment With Epigallocatechin Gallate; A Natural CompounD in Green Tea
ClinicalTrials.gov study NCT05364008. IPD Sharing: YES. Countries: 1. Publications: 1.
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
ClinicalTrials.gov study NCT05195918. IPD Sharing: NO. Countries: 1. Publications: 28.
Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool
ClinicalTrials.gov study NCT01699711. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Epigallocatechin Gallate (EGCG) to Improve Cognitive Performance in Foetal Alcohol Syndrome (FAS) Children
ClinicalTrials.gov study NCT02558933. IPD Sharing: UNDECIDED. Countries: 1. Publications: 5.
"Using Epigallocatechin Gallate (EGCG) and Cognitive Training to Modulate Cognitive Performance in Patients With Fragile X Syndrome" (TESFX)
ClinicalTrials.gov study NCT01855971. IPD Sharing: NO. Countries: 1. Publications: 9.
Effect of Green Tea (Epigallocatechin Gallate) on Albuminuria in Patients With Diabetic Nephropathy.
ClinicalTrials.gov study NCT01923597. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Figure 6 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 6 Anti-proliferation effect of EGCG and baicalin in combination treatment against EMT-6/V different doses of EGCG with a fixed dose of baicalin (70 µM).
Figure 17 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 17 Effect of baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, Positive control (PBS and tween 20%), and healthy group on serum AST average level measured by (IU/L) in EMT-6/P.
Figure 18 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 18 Effect of baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, Positive control (PBS and tween 20%), and healthy group on serum AST average level measured by (IU/L) in EMT-6/V.
Figure 13 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 13 The volume change (mm3) for treatment groups in vivo for EMT-6/P and EMT-6/V. Only statistically significant associations are shown. Positive control (PBS and tween 20%), baicalin 75 mg/kg/day, EGCG: 50 mg/kg/day, baicalin and EGCG combination 75 and 50 mg/kg/day respectively, vincristine 2mg/kg/every other day, and same doses were used in the triple therapy.
Figure 22 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 22 Effect of baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, positive control (PBS and tween 20%), and healthy group on average creatinine measured by (mg/dl) in EMT-6/V.
Figure 7 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 7 Caspase concentrations in (ng/ml) for each treatment group in EMT-6/V. Concentrations used were: baicalin 175 µM, EGCG 125 µM, baicalin and EGCG 140 and 100 µM respectively, vincristine 643 µg/ml, and positive control treated with MEM.
Figure 10 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 10 A plot of change in average tumor size (mm³) vs. time in (days) of treatment in the EMT-6/P cell line.
Figure 16 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 16 Effect of baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, positive control (PBS and tween 20%), and healthy group on serum ALT level measured by (IU/L) in EMT-6/V.
Figure 15 from: Awajan D, Abu-Humaidan AHA, Talib WH (2024) Study of the antitumor activity of the combination baicalin and epigallocatechin gallate in a murine model of vincristine-resistant breast cancer. Pharmacia 71: 1-20. https://doi.org/10.3897/pharmacia.71.e113446
Figure 15 Effect of baicalin (75 mg/kg/day), EGCG (50 mg/kg/day), a combination of baicalin and EGCG (75 and 50 mg/kg/day) respectively, vincristine 2 mg/kg/every other day, combination with vincristine (75 and 50 mg/kg/day) for combination and (2 mg/kg/every other day) for vincristine, positive control (PBS and tween 20%), and healthy group on serum ALT level measured by (IU/L) in EMT-6/P.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.